BioMarin reinstated with a Neutral at Goldman Sachs
Goldman Sachs reinstated coverage of BioMarin (BMRN) with a Neutral rating and $69 price target following the completion of the Amicus acquisition. While the shares are trading around the value…
Fiscal Year: January - December
BioMarin Pharmaceutical Inc. (BMRN), listed on the NASDAQ, has a market capitalization of $10.35B. As of May 11, 2026, the stock is trading at $53.55 per share@else an unavailable price , offering investors a clear view of its current market value. BioMarin Pharmaceutical Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 38.36, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. BioMarin Pharmaceutical Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that BioMarin Pharmaceutical Inc. (BMRN) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for BioMarin Pharmaceutical Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for BioMarin Pharmaceutical Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for BioMarin Pharmaceutical Inc. is 13.62, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, BioMarin Pharmaceutical Inc. (BMRN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether BioMarin Pharmaceutical Inc. (BMRN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of BioMarin Pharmaceutical Inc. (BMRN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of BioMarin Pharmaceutical Inc.. To access the full SS Score, consider upgrading your subscription.
BioMarin Pharmaceutical Inc. is a significant player in the industry sector, with a market capitalization of $10.35B and a competitive P/E ratio of 38.36. Investors should compare these metrics with industry peers to gauge whether BioMarin Pharmaceutical Inc. is outperforming or underperforming within its sector.
Goldman Sachs reinstated coverage of BioMarin (BMRN) with a Neutral rating and $69 price target following the completion of the Amicus acquisition. While the shares are trading around the value…
Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $116 from $104 and keeps a Buy rating on the shares. The firm said 1Q26 earnings delivered…
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BioMarin (BMRN) to $119 from $120 and keeps an Overweight rating on the shares. Q1 reinforces a near-term transition…
Evercore ISI raised the firm’s price target on BioMarin (BMRN) to $120 from $110 and keeps an Outperform rating on the shares.
Bernstein analyst William Pickering lowered the firm’s price target on BioMarin (BMRN) to $82 from $94 and keeps an Outperform rating on the shares. The firm notes revenue beat by…
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growt...
BioMarin (BMRN) Pharmaceutical announced new research from studies of Voxzogo in children with achondroplasia demonstrating positive impact on important health indicators, including arm span and bone ...
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with ...
BioMarin Pharmaceutical(BMRN) said that it completed the previously announced agreement to acquire Amicus Therapeutics (FOLD) for $14.50 per share in an all-cash transaction for a total equity value o...
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects to ...
SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conf...
Morgan Stanley analyst Sean Laaman resumed coverage of BioMarin (BMRN) with an Overweight rating with a price target of $120, up from $98. The Amicus (FOLD) acquisition does not eliminate…
BioMarin (BMRN) Pharmaceutical said that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company’s Annual Meeting of Stockholders…
Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif.
BioMarin (BMRN) announced Monday the discontinuation of three Voxzogo Phase 2 studies in Turner Syndrome, SHOX-difficiency, and ACAN-difficiency, due to several cases of Slipped Capital Femoral Epiphy...
BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, se...
BioMarin (BMRN) announced its decision to discontinue dosing and enrollment in its Phase 2 trials for Voxzogo in Turner syndrome, SHOX-deficiency and aggrecan-deficiency following the occurrence of se...
BioMarin (BMRN) announced positive new data from studies of Voxzogo – vosoritide – in children with achondroplasia in ongoing clinical trials and real-world studies. The latest findings reinforce the ...
New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, buildin...
BofA lowered the firm’s price target on BioMarin (BMRN) to $85 from $97 and keeps a Buy rating on the shares. The firm, which updated its outlook for the pro-forma…
Barclays raised the firm’s price target on BioMarin (BMRN) to $105 from $80 and keeps an Overweight rating on the shares. The firm updated the company’s model to include Amicus…
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 972.00M | Analyst x1 | |
| 2027 | 1,087.00M | 11.83% | Analyst x3 |
| 2028 | 1,368.00M | 25.85% | Analyst x3 |
| 2029 | 1,481.00M | 8.26% | Analyst x3 |
| 2030 | 1,593.67M | 7.61% | Analyst x3 |
| 2031 | 1,662.75M | 4.34% | Est @4.3% |
| 2032 | 1,726.48M | 3.83% | Est @3.8% |
| 2033 | 1,786.56M | 3.48% | Est @3.5% |
| 2034 | 1,840.46M | 3.02% | Est @3.0% |
| 2035 | 1,893.02M | 2.86% | Est @2.9% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 487.42M | 1.00 | 487.42M |
| 2025A | 724.96M | 1.00 | 724.96M |
| 2026E | 972.00M | 1.07 | 904.32M |
| 2027E | 1.09B | 1.16 | 940.90M |
| 2028E | 1.37B | 1.24 | 1.10B |
| 2029E | 1.48B | 1.33 | 1.11B |
| 2030E | 1.59B | 1.43 | 1.11B |
| 2031E | 1.66B | 1.54 | 1.08B |
| 2032E | 1.73B | 1.66 | 1.04B |
| 2033E | 1.79B | 1.78 | 1.00B |
| 2034E | 1.84B | 1.91 | 961.27M |
| 2035E | 1.89B | 2.06 | 919.89M |
| Terminal | 38.93B | 2.06 | 18.92B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.